Trial Profile
A phase II study of temozolomide in the treatment of patients with metastatic non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Sep 2005 New trial record.